Business Standard

Power crisis brewing in China likely to hit Indian pharma companies

Delays in consignments, rising prices of key ingredients worry industry

Pharma Sector, Pharma Companies
Premium

IPA members account for 60 per cent of the domestic market and about 80 per cent of India’s exports of pharmaceutical products.

Sohini Das Mumbai
The power crisis brewing in China may throw the Indian pharma market off gear if the situation continues for a few more months, feel sources in the local industry. Indian players roughly import 66-70 per cent of their bulk drug requirements from China.
 
Already, prices of active pharmaceutical ingredients (APIs), raw materials to make drugs, have gone up significantly and there are delays in shipments to India.
 
Sudarshan Jain, secretary general of the Indian Pharmaceutical Alliance (IPA), the umbrella organisation of big pharma players in India, said prices of APIs have started going up. “Prices of Penicillin-G from

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Oct 28 2021 | 6:05 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com